Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Your meds arrive with one-day shipping, and tracking is available via email and the patient portal
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Until then, the notification said GLP-1 RAs should only be prescribed for their licensed indication, and clinicians should avoid initiating people with T2DM on GLP-1 RAs for the duration of the national shortage
moderate gastrointestinal side effects (nausea 1221%)
Patients should evaluate treatment protocols alongside pricing considerations when selecting their healthcare partners
US$ 25.37
US$ 21.91
US$ 24.51
US$ 25.67
US$ 29.33
US$ 22.58
